The drug repurposing market growth is driven by the need to reduce the time needed to develop new drugs followed by the need to reuse the other elements discarded while manufacturing the older version of the medicine.
Drug repurposing has been proving to be beneficial for multiple tumors, thereby raising the convenience quotient (CQ) of the patients and healthcare providers alike.
The companies operating in drug repurposing market are collaborating with researchers to incorporate a computer model using the previously existing data that would help in testing the drug on the isolated cancer cells. Use of AI is also being explored, which would help in prediction of accurate dosage to raise the success bar of drug repositioning.
Drug repositioning means investigation of existing drugs to serve new therapeutic purposes.
As per the National Institutes of Health, over 35% of the transformative drugs that the U.S. FDA has approved can be categorized as repurposed ones.
The last few years have witnessed investigation of antifungal agents such as ketoconazole and clotrimazole for anti-trypanosome therapy. Moreover, successful repositioning of the antimicrobials has resulted in discovery of the broad-spectrum therapeutics, which are effective against multiple infection.
Drug repurposing has been reported to heavily benefit from the advancements in network biology, human genomics, and chemoproteomics. It is thus possible to identify the repurposing candidates by locating genes involved in specific disease and checking if the interaction is proper with the other genes that are targets of known drugs.
However, there could be challenges regarding acquisition of intellectual property rights and ultimately the regulatory approval for the repurposed drugs.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Drug repositioning constitutes a new-fangled way of handling the drug compounds as well as targets that were de-risked at the time of development, which, in turn, accelerates the drug development process and saves on money. The drug could thus be produced with lesser efforts and marketed with a noticeable profit margin.
Drug repurposing allows the compounds to do away with Phase I, which reduces the overall time to launch the drug to the market. Moreover, the last few years have seen a limited number of drugs hitting the market.
Therefore, the companies operating in drugs market are showing interest in drug repositioning in order to determine newer indications for older drugs, which were categorized as drugs that have been marketed successfully, drugs with no exclusive indications and safety concerns in the clinical trials, and the drugs that were terminated owing to budget concerns.
Need to optimize time regarding drug development is thus a major factor contributing toward drug repurposing market growth.
Drug repurposing revolves around the fact that several approved medicines along with the discarded compounds have been tested in humans before and sizably comprehensive information is available regarding pharmacology, probable toxicity, dose, and formulation.
The oncology vertical has readily adopted drug repositioning/recycling approach. Though the oncology drugs are basically developed for cancer of a peculiar type, they could be clinically investigated in the other similar kinds of tumor, which could produce versatile drugs.
Along these lines, Keytruda (pembrolizumab) from Merck is a prominent cancer immunotherapy approved for 14 types of cancer in the current scenario. They include lymphoma and lung cancer as well.
Arzerra (ofatumumab), a monoclonal antibody targeting CD20 protein, was initially devised by Novartis in order to treat chronic lymphocytic leukemia (CLL). However, various clinical trials are being conducted in order to determine the effectiveness of this antibody as treatment for the adults suffering from the relapsing forms of multiple sclerosis (MS).
Continual utilization of the potential to refurbish drugs for multiple purposes is thus expanding the drug repurposing market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest drug repurposing market analysis, North America dominated the drug repositioning landscape in 2023 and the scenario is expected to remain unchanged during the forecast period. This is attributed to the U.S. witnessing sizable number of R&D activities with the regulatory bodies fast-tracking the approval of medicines post repurposing.
Europe’s significant drug repurposing market share is ascribed to regulatory organizations such as European medicines Agency (EMA) facilitating approval of the repurposed medicines. Asia Pacific’s drug repurposing industry is bound to grow with increase in awareness regarding the importance of drug repurposing.
The key players in drug repurposing market are looking forward to increase the frequency of the number of services delivered regarding drug positioning.
Algernon Pharmaceuticals, Biovista Inc., Celentyx Ltd., ChemBio Discovery Inc., Chord Therapeutics SA, Excelra, Fios Genomics Ltd., Lantern Pharma Inc., Novartis AG Paradigm Biopharmaceuticals Limited Predictive Oncology Segue Therapeutics, LLC, and Teva Pharmaceutical Industries Ltd. are some of the key players covered in the drug repurposing market.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 28.9 Bn |
| Market Forecast (Value) in 2034 | US$ 47.8 Bn |
| Growth Rate (CAGR) | 4.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 28.9 Bn in 2023
It is projected to grow at a CAGR of 4.7% from 2024 to 2034
Need to reduce drug development pipeline and utilize potential to reuse
Hospitals & clinics segment accounted for the largest share in 2023
North America was the dominant region in 2023
Algernon Pharmaceuticals, Biovista Inc., Celentyx Ltd., ChemBio Discovery Inc., Chord Therapeutics SA, Excelra, Fios Genomics Ltd., Lantern Pharma Inc., Novartis AG Paradigm Biopharmaceuticals Limited Predictive Oncology Segue Therapeutics, LLC, and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Drug Repurposing Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Drug Repurposing Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Repurposing Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Indication, 2020-2034
6.3.1. Oncology
6.3.2. CNS Diseases
6.3.3. Neurodegenerative Diseases
6.3.4. Others (Rare Disorders, etc.)
6.4. Market Attractiveness Analysis, by Disease Indication
7. Global Drug Repurposing Market Analysis and Forecast, by Approach Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Approach Type, 2020-2034
7.3.1. Disease-centric approach
7.3.2. Target-centric approach
7.3.3. Drug-centric approach
7.4. Market Attractiveness Analysis, by Approach Type
8. Global Drug Repurposing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Surgery Diseases
8.3.3. Others (Research Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Drug Repurposing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Drug Repurposing Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Indication, 2020-2034
10.3.1. Oncology
10.3.2. CNS Diseases
10.3.3. Neurodegenerative Diseases
10.3.4. Others (Rare Disorders, etc.)
10.4. Market Value Forecast, by Approach Type, 2020-2034
10.4.1. Disease-centric approach
10.4.2. Target-centric approach
10.4.3. Drug-centric approach
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals & Clinics
10.5.2. Ambulatory Surgery Diseases
10.5.3. Others (Research Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease Indication
10.7.2. By Approach Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Drug Repurposing Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Indication, 2020-2034
11.3.1. Oncology
11.3.2. CNS Diseases
11.3.3. Neurodegenerative Diseases
11.3.4. Others (Rare Disorders, etc.)
11.4. Market Value Forecast, by Approach Type, 2020-2034
11.4.1. Disease-centric approach
11.4.2. Target-centric approach
11.4.3. Drug-centric approach
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals & Clinics
11.5.2. Ambulatory Surgery Diseases
11.5.3. Others (Research Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease Indication
11.7.2. By Approach Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Drug Repurposing Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Indication, 2020-2034
12.3.1. Oncology
12.3.2. CNS Diseases
12.3.3. Neurodegenerative Diseases
12.3.4. Others (Rare Disorders, etc.)
12.4. Market Value Forecast, by Approach Type, 2020-2034
12.4.1. Disease-centric approach
12.4.2. Target-centric approach
12.4.3. Drug-centric approach
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals & Clinics
12.5.2. Ambulatory Surgery Diseases
12.5.3. Others (Research Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease Indication
12.7.2. By Approach Type
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Drug Repurposing Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Indication, 2020-2034
13.3.1. Oncology
13.3.2. CNS Diseases
13.3.3. Neurodegenerative Diseases
13.3.4. Others (Rare Disorders, etc.)
13.4. Market Value Forecast, by Approach Type, 2020-2034
13.4.1. Disease-centric approach
13.4.2. Target-centric approach
13.4.3. Drug-centric approach
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals & Clinics
13.5.2. Ambulatory Surgery Diseases
13.5.3. Others (Research Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease Indication
13.7.2. By Approach Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Drug Repurposing Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Disease Indication, 2020-2034
14.3.1. Oncology
14.3.2. CNS Diseases
14.3.3. Neurodegenerative Diseases
14.3.4. Others (Rare Disorders, etc.)
14.4. Market Value Forecast, by Approach Type, 2020-2034
14.4.1. Disease-centric approach
14.4.2. Target-centric approach
14.4.3. Drug-centric approach
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals & Clinics
14.5.2. Ambulatory Surgery Diseases
14.5.3. Others (Research Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease Indication
14.7.2. By Approach Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Algernon Pharmaceuticals
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Biovista Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Celentyx Ltd.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. ChemBio Discovery Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Chord Therapeutics SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Excelra
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Fios Genomics Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Lantern Pharma Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Novartis AG
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Paradigm Biopharmaceuticals Limited
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Predictive Oncology
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Segue Therapeutics, LLC
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Teva Pharmaceutical Industries Ltd.
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
List of Tables
Table 01: Global Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 02: Global Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034
Table 03: Global Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Drug Repurposing Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Drug Repurposing Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 07: North America Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034
Table 08: North America Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 09: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 11: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034
Table 12: Europe Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 15: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034
Table 16: Asia Pacific Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 19: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034
Table 20: Latin America Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 23: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by Approach Type, 2020-2034
Table 24: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Drug Repurposing Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Drug Repurposing Market Revenue (US$ Bn), by Disease Indication, 2023
Figure 03: Global Drug Repurposing Market Value Share, by Disease Indication, 2023
Figure 04: Global Drug Repurposing Market Revenue (US$ Bn), by Approach Type, 2023
Figure 05: Global Drug Repurposing Market Value Share, by Approach Type, 2023
Figure 06: Global Drug Repurposing Market Revenue (US$ Bn), by End-user, 2023
Figure 07: Global Drug Repurposing Market Value Share, by End-user, 2023
Figure 08: Global Drug Repurposing Market Value Share, by Region, 2023
Figure 09: Global Drug Repurposing Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 11: Global Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034
Figure 13: Global Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034
Figure 14: Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Drug Repurposing Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Drug Repurposing Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Drug Repurposing Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 22: North America Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034
Figure 23: North America Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034
Figure 26: North America Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 31: Europe Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034
Figure 32: Europe Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034
Figure 35: Europe Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 40: Asia Pacific Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034
Figure 41: Asia Pacific Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034
Figure 44: Asia Pacific Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Drug Repurposing Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 49: Latin America Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034
Figure 50: Latin America Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034
Figure 53: Latin America Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Drug Repurposing Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Drug Repurposing Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Drug Repurposing Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 58: Middle East & Africa Drug Repurposing Market Value Share Analysis, by Approach Type, 2023 and 2034
Figure 59: Middle East & Africa Drug Repurposing Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by Approach Type, 2024-2034
Figure 62: Middle East & Africa Drug Repurposing Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug Repurposing Market
